Takeda Seeks to Remedy Crohn's Disease, Ulcerative Colitis in US

Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States

Source: PharmaManufacturing.com - June 24, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news